92 related articles for article (PubMed ID: 30836926)
1. Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.
Umamaheswari A; Puratchikody A; Hari N
Anticancer Agents Med Chem; 2019; 19(7):916-934. PubMed ID: 30836926
[TBL] [Abstract][Full Text] [Related]
2. Design and Synthesis of Dihydroxamic Acids as HDAC6/8/10 Inhibitors.
Morgen M; Steimbach RR; Géraldy M; Hellweg L; Sehr P; Ridinger J; Witt O; Oehme I; Herbst-Gervasoni CJ; Osko JD; Porter NJ; Christianson DW; Gunkel N; Miller AK
ChemMedChem; 2020 Jul; 15(13):1163-1174. PubMed ID: 32348628
[TBL] [Abstract][Full Text] [Related]
3. Identification of a Histone Deacetylase 8 Inhibitor through Drug Screenings Based on Machine Learning.
Nurani A; Yamashita Y; Taki Y; Takada Y; Itoh Y; Suzuki T
Chem Pharm Bull (Tokyo); 2024; 72(2):173-178. PubMed ID: 38296560
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors.
Sodji QH; Patil V; Kornacki JR; Mrksich M; Oyelere AK
J Med Chem; 2013 Dec; 56(24):9969-81. PubMed ID: 24304348
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Amine-based Histone Deacetylase Inhibitors.
Abdelkarim H; Neelarapu R; Madriaga A; Vaidya AS; Kastrati I; Karumudi B; Wang YT; Taha TY; Thatcher GRJ; Frasor J; Petukhov PA
ChemMedChem; 2017 Dec; 12(24):2030-2043. PubMed ID: 29080240
[TBL] [Abstract][Full Text] [Related]
6. Quinazoline-chalcone hybrids as HDAC/EGFR dual inhibitors: Design, synthesis, mechanistic, and in-silico studies of potential anticancer activity against multiple myeloma.
Mansour MA; AboulMagd AM; Abbas SH; Abdel-Aziz M; Abdel-Rahman HM
Arch Pharm (Weinheim); 2024 May; 357(5):e2300626. PubMed ID: 38297894
[TBL] [Abstract][Full Text] [Related]
7. Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities.
Zhao N; Yang F; Han L; Qu Y; Ge D; Zhang H
Molecules; 2020 Feb; 25(3):. PubMed ID: 32046013
[TBL] [Abstract][Full Text] [Related]
8. Evaluation and molecular docking study of two flavonoids from Oroxylum indicum (L.) Kurz and their semi-synthetic derivatives as histone deacetylase inhibitors.
Somsakeesit LO; Senawong T; Senawong G; Kumboonma P; Samankul A; Namwan N; Yenjai C; Phaosiri C
J Nat Med; 2024 Jan; 78(1):236-245. PubMed ID: 37991632
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: in-silico studies, synthesis, and biological evaluation.
Upadhyay N; Tilekar K; Jänsch N; Schweipert M; Hess JD; Henze Macias L; Mrowka P; Aguilera RJ; Choe JY; Meyer-Almes FJ; Ramaa CS
Bioorg Chem; 2020 Jul; 100():103934. PubMed ID: 32446120
[TBL] [Abstract][Full Text] [Related]
10. Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual-Targeting HDAC Inhibitors and HDAC Degraders (PROTACs).
Sinatra L; Bandolik JJ; Roatsch M; Sönnichsen M; Schoeder CT; Hamacher A; Schöler A; Borkhardt A; Meiler J; Bhatia S; Kassack MU; Hansen FK
Angew Chem Int Ed Engl; 2020 Dec; 59(50):22494-22499. PubMed ID: 32780485
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of 1,10-phenanthroline-based hydroxamate derivative as dual histone deacetylases/ribonucleotide reductase inhibitor with antitumor activities.
Shetty MG; Pai P; Dey B; Satyamoorthy K; Shil S; Nayak UY; T A; Sundara BK
Daru; 2024 Jun; 32(1):263-278. PubMed ID: 38683491
[TBL] [Abstract][Full Text] [Related]
12. Molecular design, synthesis and
Abdel-Atty MM; Farag NA; Serya RAT; Abouzid KAM; Mowafy S
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1290-1312. PubMed ID: 34187263
[TBL] [Abstract][Full Text] [Related]
13. Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase.
Raji I; Yadudu F; Janeira E; Fathi S; Szymczak L; Kornacki JR; Komatsu K; Li JD; Mrksich M; Oyelere AK
Bioorg Med Chem; 2017 Feb; 25(3):1202-1218. PubMed ID: 28057407
[TBL] [Abstract][Full Text] [Related]
14. A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy.
Patel HK; Siklos MI; Abdelkarim H; Mendonca EL; Vaidya A; Petukhov PA; Thatcher GR
ChemMedChem; 2014 Mar; 9(3):602-13. PubMed ID: 23956109
[TBL] [Abstract][Full Text] [Related]
15. Extending the use of tadalafil scaffold: Development of novel selective phosphodiesterase 5 inhibitors and histone deacetylase inhibitors.
ElHady AK; Shih SP; Chen YC; Liu YC; Ahmed NS; Keeton AB; Piazza GA; Engel M; Abadi AH; Abdel-Halim M
Bioorg Chem; 2020 May; 98():103742. PubMed ID: 32199305
[TBL] [Abstract][Full Text] [Related]
16. Discovery of histone deacetylase 8 selective inhibitors.
Tang W; Luo T; Greenberg EF; Bradner JE; Schreiber SL
Bioorg Med Chem Lett; 2011 May; 21(9):2601-5. PubMed ID: 21334896
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors through click chemistry.
Shen J; Woodward R; Kedenburg JP; Liu X; Chen M; Fang L; Sun D; Wang PG
J Med Chem; 2008 Dec; 51(23):7417-27. PubMed ID: 19007204
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and evaluation of antiproliferative activity of melanoma-targeted histone deacetylase inhibitors.
Raji I; Ahluwalia K; Oyelere AK
Bioorg Med Chem Lett; 2017 Feb; 27(4):744-749. PubMed ID: 28131715
[TBL] [Abstract][Full Text] [Related]
19. The antileishmanial activity of isoforms 6- and 8-selective histone deacetylase inhibitors.
Sodji Q; Patil V; Jain S; Kornacki JR; Mrksich M; Tekwani BL; Oyelere AK
Bioorg Med Chem Lett; 2014 Oct; 24(20):4826-30. PubMed ID: 25240614
[TBL] [Abstract][Full Text] [Related]
20. Development of Fluorinated Peptoid-Based Histone Deacetylase (HDAC) Inhibitors for Therapy-Resistant Acute Leukemia.
Reßing N; Schliehe-Diecks J; Watson PR; Sönnichsen M; Cragin AD; Schöler A; Yang J; Schäker-Hübner L; Borkhardt A; Christianson DW; Bhatia S; Hansen FK
J Med Chem; 2022 Nov; 65(22):15457-15472. PubMed ID: 36351184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
